Acute Porphyria Drug Database

M01AE17 - Dexketoprofen
Propably not porphyrinogenic
PNP

Rationale
Ketoprofen is a substrate of CYP2C9. It is not listed as a mechanism-based inhibitor or inducer of any CYP enzymes and is therefore regarded as probably not porphyrinogenic. This classification is supported by 45 clinical reports of uneventful use. Risk for gastrointestinal adverse events in the form of nausea, vomiting, abdominal pain, diarrhoea and dyspepsia motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Dexketoprofen is the S-(+)-enantiomer of ketoprofen.
Therapeutic characteristics
Dexketoprofen is indicated for the treatment of symptomatic treatment of pain of mild to moderate intensity, such as musculoskeletal pain, dysmenorrhoea and dental pain. Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, abdominal pain, diarrhoea and dyspepsia.
Metabolism and pharmacokinetics
Ketoprofen exhibits little stereoselectivity in its pharmacokinetics. The data generated using non-stereospecific assays may therefore be used to explain the pharmacokinetics of individual enantiomers (Jamali 1990). Ketoprofen is listed as a substrate of CYP2C9 (Holstein 2012 and Zhou 2009). Dexketoprofen is not bioinverted to R-(-)-ketoprofen in humans (Baranoj 2001). Ketoprofen is glucuroconjugated and excreted in urine (Jamali 1990). Half-life elimination is 1.5-4 hours.
Published experience
Ketoprofen (the racemate mixture with R- and dexketoprofen) is listed as thought to be safe for use in acute porphyria (Moore 1997).
IPNet drug reports
Ketoprofen (the racemate mixture with R- and dexketoprofen): uneventful use reported in 45 patients with acute porphyria.

References

  1. Scientific articles
  2. Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet. 2001;40(4):245-62. PMID 11368291. #2372
  3. Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1549-63. PMID 23153186. #1004
  4. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet. 1990 Sep;19(3):197-217. PMID 2203580. #2373
  5. Moore MR, Hift RJ. Drugs in the acute porphyrias--toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):89-94. PMID 9074793. #1110
  6. Zhou SF, Zhou ZW, et al. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. PMID 19515014. #4527

Similar drugs
Explore alternative drugs in similar therapeutic classes M01A / M01AE or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙